Review of the advances on respiratory syncytial virus vaccine
10.13431/j.cnki.immunol.j.20240085
- VernacularTitle:呼吸道合胞病毒疫苗研究进展
- Author:
Sun LI
1
;
Dece SUN
;
Xiaoyang LI
;
Xinmiao WEI
;
Yang YANG
;
Yuantong QI
;
Hua YANG
;
Qianfei ZUO
;
Yanping SONG
;
Mingmin JIANG
;
Qing LAN
;
Tao MA
Author Information
1. 121000 锦州,中国人民解放军联勤保障部队第968医院医疗保障中心
- Publication Type:Journal Article
- Keywords:
Respiratory syncytial virus;
Vaccine
- From:
Immunological Journal
2024;40(7):609-615
- CountryChina
- Language:Chinese
-
Abstract:
Respiratory syncytial virus(RSV)is a major cause of severe lower respiratory disease and can infect all populations,posing a significant health threat to infants and the elderly.After more than 60 years of research,there are only 2 RSV vaccines and 2 preventive monoclonal antibodies be licensed,but the use of the population is severely limited,expensive and difficult to large-scale popularization.RSV vaccine development faces a number of obstacles,such as the lack of animal models,avoidance of RSV immunity,and short duration of immunity.Since the failure of formalin inactivated RSV vaccine trials,RSV vaccine development has become more cautious and difficult.This article briefly reviews the research status of RSV vaccines,and introduces several representative vaccines currently under development,in order to facilitate researchers to review the latest progress and contribute to promoting vaccine research.
